Metagenomi, Inc. Common Stock (MGX) Stock

Metagenomi, Inc. Common Stock (MGX) is a Healthcare stock trading at $1.22 (as of 2026-06-18), with a market capitalization of $51.20M and a trailing P/E of -0.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Metagenomi, Inc. is a gene editing biotechnology company developing therapeutics based on metagenomics-derived genome editing tools. It focuses on in vivo human therapeutic applications through partnerships with Moderna, and gene edited T-cell receptor-based cancer therapies with Affini-T, as well as R&D and commercialization collaborations with Ionis Pharmaceuticals.

Valuation — source: SEC EDGAR (first-party)
Price	$1.22
Market Cap	$51.20M
P/E Ratio	-0.5
EV / EBITDA	-0.2
Price / Book	0.33
Price / Sales	2.02
DCF Value (model)	$-39.24
DCF Upside vs Price	-3329.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$25.21M
Net Margin	-348.5%
Return on Equity	-62.3%
Current Ratio	6.43
Revenue Growth (YoY)	-51.8%
EPS Growth (YoY)	0.0%
FCF Growth (YoY)	-20.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.07 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-102.5%
vs Industry	-103.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($2.06M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jian Irish
Employees	202
Country	US
IPO Date	2006-04-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.